MedTrace Logo

Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude

NCT03165890 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2019-05-14

No results posted yet for this study

Summary

Randomized, placebo controlled trial evaluating the effect of acetazolamide on cognition in lowlanders with chronic obstructive pulmonary disease travelling from 760 m to 3200 m.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

ACETAZOLAMIDE oral capsule

Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

DRUG

Placebo oral capsule

Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m

Sponsors & Collaborators

  • National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov

    collaborator OTHER_GOV

  • University of Zurich

    lead OTHER

Principal Investigators

  • Konrad E Bloch, MD · University of Zurich

  • Talant M Sooronbaev, MD · National Center of Cardiology and Internal Medicine, Bishkek, Kyrgyzstan

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-24
Primary Completion
2017-07-24
Completion
2017-07-24

Countries

  • Kyrgyzstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03165890 on ClinicalTrials.gov